Taja-Chayeb Lucia, Candelaria Myrna, Brom Rocio, Trejo-Becerril Catalina, Meza Fabian, Duenas-Gonzalez Alfonso
Unidad de Investigación Biomédica en Cancer, Instituto Nacional de Cancerología/Instituto de Investigaciones Biomédicas, Ave San Fernando #22, Col. Sección XVI, Tlalpan 14080, UNAM, Mexico City.
Lung Cancer. 2005 Nov;50(2):259-63. doi: 10.1016/j.lungcan.2005.05.015. Epub 2005 Jul 11.
Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib. Responses to TK inhibitors in the absence of EGFR gene mutation for BAC patients have not been reported. A case of a patient with BAC refractory to chemotherapy who responded to gefitinib in the absence of EGFR gene mutations is reported. Tyrosine kinase inhibitors may have a role in BAC in the absence of EGFR gene mutations. Additional studies on other molecular alterations of the EGFR family members are needed to better predict response to these agents.
非小细胞肺癌中表皮生长因子受体（EGFR）基因的酪氨酸激酶（TK）结构域突变与这些癌症对抑制EGFR激酶活性的药物（如吉非替尼和厄洛替尼）的敏感性增加有关。对于细支气管肺泡癌（BAC）患者，在没有EGFR基因突变的情况下对TK抑制剂的反应尚未见报道。本文报道了1例化疗难治性BAC患者在没有EGFR基因突变的情况下对吉非替尼有反应。在没有EGFR基因突变的情况下，酪氨酸激酶抑制剂可能在BAC中发挥作用。需要对EGFR家族成员的其他分子改变进行更多研究，以更好地预测对这些药物的反应。
